Page last updated: 2024-09-03

tyrosyl-leucyl-n-methylphenylalanyl-glutaminyl-prolyl-glutaminyl-arginyl-phenylalaninamide and naltrexone

tyrosyl-leucyl-n-methylphenylalanyl-glutaminyl-prolyl-glutaminyl-arginyl-phenylalaninamide has been researched along with naltrexone in 3 studies

Compound Research Comparison

Studies
(tyrosyl-leucyl-n-methylphenylalanyl-glutaminyl-prolyl-glutaminyl-arginyl-phenylalaninamide)
Trials
(tyrosyl-leucyl-n-methylphenylalanyl-glutaminyl-prolyl-glutaminyl-arginyl-phenylalaninamide)
Recent Studies (post-2010)
(tyrosyl-leucyl-n-methylphenylalanyl-glutaminyl-prolyl-glutaminyl-arginyl-phenylalaninamide)
Studies
(naltrexone)
Trials
(naltrexone)
Recent Studies (post-2010) (naltrexone)
18008,7451,2282,642

Protein Interaction Comparison

ProteinTaxonomytyrosyl-leucyl-n-methylphenylalanyl-glutaminyl-prolyl-glutaminyl-arginyl-phenylalaninamide (IC50)naltrexone (IC50)
Cytochrome P450 2D6Homo sapiens (human)1
Delta-type opioid receptorMus musculus (house mouse)0.0051
Delta-type opioid receptorRattus norvegicus (Norway rat)0.0063
Kappa-type opioid receptorMus musculus (house mouse)0.006
Mu-type opioid receptorRattus norvegicus (Norway rat)0.0005
Kappa-type opioid receptorRattus norvegicus (Norway rat)0.0005
Mu-type opioid receptorHomo sapiens (human)0.006
Delta-type opioid receptorHomo sapiens (human)0.0319
Kappa-type opioid receptorCavia porcellus (domestic guinea pig)0.0093
Kappa-type opioid receptorHomo sapiens (human)0.0377
Mu-type opioid receptorMus musculus (house mouse)0.0076
Mu-type opioid receptorCavia porcellus (domestic guinea pig)0.0004

Research

Studies (3)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's2 (66.67)18.2507
2000's1 (33.33)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Desprat, C; Zajac, JM1
Coudoré-Civiale, MA; Courteix, C; Eschalier, A; Fialip, J; Privat, AM; Zajac, JM1
Ballet, S; Bourgoin, S; Braz, J; Cesselin, F; Hamon, M; Mauborgne, A; Zajac, JM1

Other Studies

3 other study(ies) available for tyrosyl-leucyl-n-methylphenylalanyl-glutaminyl-prolyl-glutaminyl-arginyl-phenylalaninamide and naltrexone

ArticleYear
Differential modulation of mu- and delta-opioid antinociception by neuropeptide FF receptors in young mice.
    Neuropeptides, 1997, Volume: 31, Issue:1

    Topics: Age Factors; Analgesics, Opioid; Animals; Enkephalin, Ala(2)-MePhe(4)-Gly(5)-; Enkephalins; Male; Mice; Mice, Inbred Strains; Morphine; Naltrexone; Narcotic Antagonists; Neuropeptides; Nociceptors; Oligopeptides; Receptors, Neuropeptide; Receptors, Opioid, delta; Receptors, Opioid, mu

1997
Spinal effect of a neuropeptide FF analogue on hyperalgesia and morphine-induced analgesia in mononeuropathic and diabetic rats.
    British journal of pharmacology, 1999, Volume: 127, Issue:6

    Topics: Analgesia; Analgesics; Analgesics, Opioid; Animals; Behavior, Animal; Diabetes Mellitus, Experimental; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Therapy, Combination; Hyperalgesia; Injections, Spinal; Male; Morphine; Naltrexone; Narcotic Antagonists; Nervous System Diseases; Oligopeptides; Pain; Rats; Rats, Sprague-Dawley; Somatostatin; Time Factors; Vocalization, Animal

1999
The neuropeptide FF analogue, 1DMe, reduces in vivo dynorphin release from the rat spinal cord.
    Journal of neurochemistry, 2002, Volume: 81, Issue:3

    Topics: Animals; Dose-Response Relationship, Drug; Dynorphins; Injections, Spinal; Male; Models, Animal; Naltrexone; Narcotic Antagonists; Oligopeptides; Peptide Fragments; Perfusion; Radioimmunoassay; Rats; Rats, Sprague-Dawley; Receptors, Opioid, delta; Receptors, Opioid, kappa; Receptors, Opioid, mu; Somatostatin; Spinal Cord

2002